Abstract
RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of interest in vitro, exploring a naturally occurring catalytic mechanism. Beyond functional analyses, the downregulation of pathologically relevant genes which are aberrantly expressed in a given disease will offer novel therapeutic approaches, also with regard to otherwise ‘undruggable’ genes. RNAi is mediated by small interfering RNAs (siRNA), and thus siRNA delivery in vivo is of critical importance for its implementation. Due to the instability and physicochemical properties of siRNAs, the development of strategies and formulations for siRNA protection, cellular uptake, correct intracellular localization and endosomal release, in combination with favourable pharmacokinetic properties, preferential delivery to the target organ, high biocompatibility and absence of unwanted side effects is crucial for the success of RNAi-based therapeutics. Approaches include the encapsulation in lipids, the complex formation with a variety of liposomes or cationic polymers, the chemical conjugation of siRNAs for example to peptides, aptamers or antibodies as well as other formulations. This review discusses non-viral strategies, based on different siRNA formulations and various modes of administration, for the delivery of therapeutic siRNAs to induce RNAi in vivo. It gives a comprehensive overview including a detailed listing of in vivo studies which have successfully employed various strategies for analytical or therapeutic siRNA-mediated gene targeting in different animal models, and presents a more in-depth description of some promising approaches with a special emphasis on polymers.
Keywords: RNA interference, small interfering RNA, RNAi, siRNA, gene targeting in vivo, polyethylenimine, in vivo siRNA delivery
Current Pharmaceutical Design
Title: Cellular Delivery In Vivo of siRNA-Based Therapeutics
Volume: 14 Issue: 34
Author(s): A. Aigner
Affiliation:
Keywords: RNA interference, small interfering RNA, RNAi, siRNA, gene targeting in vivo, polyethylenimine, in vivo siRNA delivery
Abstract: RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of interest in vitro, exploring a naturally occurring catalytic mechanism. Beyond functional analyses, the downregulation of pathologically relevant genes which are aberrantly expressed in a given disease will offer novel therapeutic approaches, also with regard to otherwise ‘undruggable’ genes. RNAi is mediated by small interfering RNAs (siRNA), and thus siRNA delivery in vivo is of critical importance for its implementation. Due to the instability and physicochemical properties of siRNAs, the development of strategies and formulations for siRNA protection, cellular uptake, correct intracellular localization and endosomal release, in combination with favourable pharmacokinetic properties, preferential delivery to the target organ, high biocompatibility and absence of unwanted side effects is crucial for the success of RNAi-based therapeutics. Approaches include the encapsulation in lipids, the complex formation with a variety of liposomes or cationic polymers, the chemical conjugation of siRNAs for example to peptides, aptamers or antibodies as well as other formulations. This review discusses non-viral strategies, based on different siRNA formulations and various modes of administration, for the delivery of therapeutic siRNAs to induce RNAi in vivo. It gives a comprehensive overview including a detailed listing of in vivo studies which have successfully employed various strategies for analytical or therapeutic siRNA-mediated gene targeting in different animal models, and presents a more in-depth description of some promising approaches with a special emphasis on polymers.
Export Options
About this article
Cite this article as:
Aigner A., Cellular Delivery In Vivo of siRNA-Based Therapeutics, Current Pharmaceutical Design 2008; 14 (34) . https://dx.doi.org/10.2174/138161208786898815
DOI https://dx.doi.org/10.2174/138161208786898815 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Store Stability as an Antiarrhythmic Endpoint
Current Pharmaceutical Design Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells
Current Cardiology Reviews Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design Glucose Metabolism and Insulin Resistance in Sepsis
Current Pharmaceutical Design Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Targeting Stenosis with Nucleotide-Hydrolyzing Enzymes
Current Pharmaceutical Biotechnology 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Proresolution Mediators and Receptors: Novel Drug Targets for Enhancing Pharmacological Armamentarium against Periodontal Inflammation
Infectious Disorders - Drug Targets Role of Endogenous Androgen Against Insulin Resistance and Athero-sclerosis in Men with Type 2 Diabetes
Current Diabetes Reviews Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews Curcumin, Hesperidin, and Rutin Selectively Interfere with Apoptosis Signaling and Attenuate Streptozotocin-Induced Oxidative Stress- Mediated Hyperglycemia
Current Neurovascular Research